This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The American Health Care Association, which lobbies on behalf of nursinghomes, did not comment on the list of 10 drugs or Medicare’s negotiating power. The Federation of American Hospitals offered no statement.
Can continuous manufacturing add shareholder value for pharmaceuticalcompanies? The current state of the pharmaceutical market is characterised by an asymmetric information problem that introduces several market imperfections. Quality rating and private-prices: Evidence from the NursingHome Industry.
Nursinghomes, dialysis centres, and long-term acute care hospitals all see considerable misuse and overuse of antimicrobials among patients who are, by definition, immunocompromised or infirm.”.
Most importantly, will this anti-amyloid drug keep people out of nursinghomes? Pharmaceuticalcompanies do not know what to make of this unexpected complication. We will have to see more data to better understand the meaning of this clinical trial. Will the drug restore memory? Another problem is brain shrinkage.
After a long period of inactivity in RSV vaccine development , two pharmaceuticalcompanies are now approaching regulatory decisions for their RSV vaccines. GAVI has created a market for the pharmaceuticalcompanies to be able to develop enough doses for these LMIC markets.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content